A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
InSightec
Study ID
NCT03028246
Status
Recruiting

Conditions

  • Benign Centrally-Located Intracranial Tumors

Eligibility Criteria

Sex
ALL
Age
5 Years - 22 Years
Healthy Volunteers
Not accepted

Interventions

  • ExAblate 4000 System — DEVICE
    Focused ultrasound

Study Details

The goal of this prospective, non-randomized, single-arm, feasibility study is to develop data to evaluate the safety and feasibility of ExAblate 4000 treatment of benign intracranial tumors which require clinical intervention in pediatric and young adult subjects. Indication of Use: Ablation of benign intracranial tumors in children and young adults which are ExAblate accessible.

Key Dates

Start date
Feb 28, 2017
Status verified
May 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ExAblate 4000 System
    MR-Guided Focused Ultrasound

Primary Outcome Measure

Incidence of Treatment-Emergent Adverse Events Safety and Tolerability [ Time Frame: Post ExAblate Procedure through 12 Month Follow-up ]

Locations (3)

FacilityCityStateZIPSite coordinators
Children's National Medical CenterWashington D.C.District of Columbia20010
Elizabeth Paronett
202-476-5551
Robert Keating (PRINCIPAL_INVESTIGATOR)
Roger Packer (SUB_INVESTIGATOR)
Nicklaus Children's HospitalMiamiFlorida33155
The Focused Ultrasound Team
305-662-8386
John Ragheb, MD
305-662-8386
John Ragheb, MD (PRINCIPAL_INVESTIGATOR)
Marytery Fajardo, MD (SUB_INVESTIGATOR)
Matt Lallas, MD (SUB_INVESTIGATOR)
Pat Dean, ARNP (SUB_INVESTIGATOR)
Texas Children's HospitalHoustonTexas77030
Sarah Martinez
832-822-4075
Daniel Curry, MD (PRINCIPAL_INVESTIGATOR)
Irfan Ali, MD (SUB_INVESTIGATOR)

Find similar trials in Washington D.C., DC